# Seralutinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/seralutinib

> The next catalyst for seralutinib, sponsored by Gossamer Bio, Inc. (GOSS), is its primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | seralutinib |
| Codes | GB002 |
| Sponsor | Gossamer Bio, Inc. (GOSS) https://sec-api.dev/companies/goss/catalysts |
| Indications | pah in september 2026, pah based in part, [pulmonary arterial hypertension](https://sec-api.dev/indications/pulmonary-arterial-hypertension), with pah in september 2026 |
| Modality | small_molecule |
| FDA designations | orphan |

## Timeline

### Dec 2022: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-03-13, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001728117-25-000081): "In December 2022, we announced positive topline results from the Phase 2 TORREY Study in PAH patients." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000081/goss-20250930.htm
- SEC Form 10-Q (accession 0001728117-25-000068): "In December 2022, we announced positive topline results from the Phase 2 TORREY Study in PAH patients." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000068/goss-20250630.htm
- SEC Form 10-Q (accession 0001728117-25-000036): "In December 2022, we announced positive topline results from the Phase 2 TORREY Study in PAH patients." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000036/goss-20250331.htm
- SEC Form 10-K (accession 0001728117-25-000021): "In December 2022, we announced positive topline results from the 24-week Phase 2 TORREY trial in 86 PAH patients." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000021/goss-20241231.htm
- SEC Form 10-K (accession 0001728117-25-000021): "In December 2022, we announced positive topline results from the Phase 2 TORREY Study in PAH patients." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000021/goss-20241231.htm
- SEC Form 10-K (accession 0001728117-25-000021): "In December 2022, we announced positive topline results from the completed Phase 2 TORREY Study, a randomized, double-blind, placebo-controlled, multi-center clinical trial in PAH patients." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000021/goss-20241231.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-03-13, last confirmed 2025-03-13.
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000022): "Topline results from the PROSERA Study are expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/goss-20250313xexx991.htm
- SEC Form 10-K (accession 0001728117-25-000021): "We expect to report topline data from the PROSERA study in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000021/goss-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000022): "- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 -" https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/goss-20250313xexx991.htm

### Feb 2026: topline data readout

- Status: completed, missed. Date confidence: month. Stage: 3.
- First seen 2025-05-15, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000082): "- Topline Results from PROSERA Phase 3 Expected in February 2026 -" https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/goss-20251105xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000082): "We expect to announce topline results from the ongoing Phase 3 PROSERA Study in February 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/goss-20251105xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000069): "- Topline Results from PROSERA Phase 3 Expected in February 2026 -" https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/goss-20250805xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000069): "We expect to announce topline results from the ongoing Phase 3 PROSERA Study in February 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/goss-20250805xexx991.htm
- SEC Form 8-K (accession 0001728117-25-000040): "The Company expects to announce topline results from the ongoing Phase 3 PROSERA Study in February 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000040/goss-20250616.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000040): "- Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 -" https://www.sec.gov/Archives/edgar/data/1728117/000172811725000040/goss-20250616xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000040): "We expect to announce topline results from the ongoing Phase 3 PROSERA Study in February 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000040/goss-20250616xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000037): "- Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 -" https://www.sec.gov/Archives/edgar/data/1728117/000172811725000037/goss-20250515xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000037): "o We expect to announce topline results from the ongoing Phase 3 PROSERA Study in February 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000037/goss-20250515xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-25-000037): "We expect to publicly announce topline data from this pivotal study in February of 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811725000037/goss-20250515xexx991.htm
- SEC Form 10-Q (accession 0001728117-26-000114): "In February 2026, we announced topline results from the Phase 3 PROSERA clinical trial of seralutinib in PAH, including that the study did not meet its primary endpoint." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000114/goss-20260930.htm
- SEC Form 10-Q (accession 0001728117-26-000072): "In February 2026, we announced topline results from the Phase 3 PROSERA clinical trial of seralutinib in PAH, including that the study did not meet its primary endpoint." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000072/goss-20260630.htm

### Jun 2026: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: PAH in September 2026.
- First seen 2026-11-10, last confirmed 2026-11-10.
- SEC Form 10-Q (accession 0001728117-26-000114): "Following a Pre-NDA Type B meeting with the FDA held in mid-June 2026 and receipt of the official meeting minutes, we submitted an NDA for seralutinib for the treatment of PAH in September 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000114/goss-20260930.htm

### September 23, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact. Stage: 3. Indication: pulmonary arterial hypertension.
- First seen 2026-05-15, last confirmed 2026-11-10.
- SEC Form 8-K (accession 0001728117-26-000104): "On September 23, 2026, Gossamer Bio, Inc. (the "Company") announced that it submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension ("PAH")." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000104/goss-20260923.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-26-000116): "Gossamer submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatment of PAH." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000116/goss-20261110xexx991xearni.htm
- SEC Form 10-Q (accession 0001728117-26-000114): "In September 2026 we submitted an NDA submission for seralutinib for the treatment of PAH based in part on our views following our meeting with the FDA and the official minutes therefrom." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000114/goss-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-26-000077): "The financing follows the Company's recent reacquisition of worldwide rights to seralutinib and is in advance of the planned NDA submission in September 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000077/ex991.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-26-000064): "Following a productive Pre-NDA Type B meeting with the U.S. Food and Drug Administration (FDA) and receipt of the official meeting minutes, the Company is proceeding toward a planned NDA submission for seralutinib for the treatment of patients with PAH in September 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000064/goss-20260727xexx991xprchi.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-26-000064): "The Company plans to submit the NDA for seralutinib in PAH in September 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000064/goss-20260727xexx991xprchi.htm
- SEC Form 8-K (accession 0001728117-26-000036): "Subject to the outcomes of the Pre-NDA meeting, the Company expects to submit an NDA for seralutinib for the treatment of PAH in September 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000036/goss-20260518.htm
- SEC Form 10-Q (accession 0001728117-26-000072): "Following a Pre-NDA Type B meeting with the FDA held in mid-June 2026 and receipt of the official meeting minutes, we plan to proceed with an NDA submission for seralutinib for the treatment of PAH in September 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000072/goss-20260630.htm
- SEC Form 10-Q (accession 0001728117-26-000032): "Subject to the outcomes of interactions with the FDA, the Company expects to submit a New Drug Application to the FDA for seralutinib for the treatment of PAH in September 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000032/goss-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001728117-26-000073): "On that basis, the Company intends to submit an NDA supported by one adequate and well-controlled study (Phase 3 PROSERA) plus confirmatory evidence (Phase 2 TORREY and supportive analyses) in September 2026." https://www.sec.gov/Archives/edgar/data/1728117/000172811726000073/goss-20260813xexx991xearni.htm

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc.." https://clinicaltrials.gov/study/NCT06274801

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Arterial Hypertension.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc.." https://clinicaltrials.gov/study/NCT06274801

## Same indication

- [YUTREPIA (treprostinil)](https://sec-api.dev/pdufa/treprostinil) (UTHR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/seralutinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Seralutinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/seralutinib

```bibtex
@misc{secapidev_pdufa_seralutinib_20261116,
  title        = {Seralutinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/seralutinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_seralutinib_20261116","title":"Seralutinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/seralutinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
